A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3

Neurology

Volumn 79, Issue 22, 2012, Pages 2218-

  Connolly, Barbara S ^a   Prashanth, L K ^a   Shah, Binit B ^a   Marras, Connie ^a   Lang, Anthony E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LETTER; NAUSEA; NIGHTMARE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINOCEREBELLAR DEGENERATION; UNSTEADINESS;

EID: 84871325226     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318278a059     Document Type: Editorial

References (3)

1. Zesiewicz TA, Greenstein MB, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012;78:545-550.
2. Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 1997;68:1511-1519.
3. Maskos U. Role of endogenous acetylcholine in the control of the dopaminergic system via nicotinic receptors. J Neurochem 2010;114:641-646.